hb0017
Small moleculeexperimental
Clinical trial activity
5 trials · 3 clinical orgs · 0 marketing orgs
Phase 1
2
Phase 2
3
Phase 3
1
Phase 4
0
Earliest trial started Oct 31, 2020 (NCT04505033)
Timeline
Indications
Mechanism of action
- Interleukin 17ASupplementation
IL17A supplementation
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT06592274 | Phase 2 | Sep 30, 2024 | Huabo Biopharm Co., Ltd. |
| NCT06477237 | Phase 3 | Mar 1, 2024 | Huabo Biopharm Co., Ltd., Peking University |
| NCT05531682 | Phase 2 | Oct 31, 2022 | Huabo Biopharm Co., Ltd., Peking University |
| NCT05442788 | Phase 1 | Sep 2, 2021 | Bengbu Medical College, Huabo Biopharm Co., Ltd. |
| NCT04505033 | Phase 1 | Oct 31, 2020 | Huabo Biopharm Co., Ltd. |
Showing 5 of 5 trials
Page 1 / 1
Organizations
Research & Development (3)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Huabo Biopharm Co., Ltd. | For profit | 5 | 5 | 3 | 2020 |
| Peking University | Academic/Hospital | 2 | 0 | 2 | 2022 |
| Bengbu Medical College | Academic/Hospital | 1 | 0 | 1 | 2021 |
3 organizations
Page 1 / 1